AGP Executive Report
Last update: 8 hours agoHepatitis B Vaccine Trial: A revised study plan in Guinea-Bissau would enroll 14,000 newborns, giving half the hepatitis B vaccine at birth and delaying it for the rest until six weeks. Babies born to mothers who test positive for the virus would be excluded. Denmark’s University of Southern Denmark and Guinea-Bissau’s ethics committee have approved the plan, but one report says final government authorization is still pending. The $1.6 million CDC-funded trial has drawn strong criticism because it delays a vaccine recommended at birth; the WHO previously said the original design fell short of recognized scientific and ethical principles.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
